Literature DB >> 8144857

Treatment of amiodarone iodine-induced thyrotoxicosis with plasmapheresis and methimazole.

F Aghini-Lombardi1, S Mariotti, P V Fosella, L Grasso, A Pinchera, L E Braverman, E Martino.   

Abstract

The present report illustrates the clinical and biochemical outcome in two amiodarone iodine-induced thyrotoxicosis (AIIT) patients submitted to plasmapheresis. Amiodarone was discontinued, and treatment with MMI (40 mg/day) was started. In addition, patients were submitted to two sessions of plasma-exchange, with a one-day interval between the two session. In both patients serum total T3 (TT3) and free T3 (FT3) concentrations decreased promptly but in contrast to the serum TT3, FT3 levels remained steadily above the normal range. A similar behaviour was observed for total T4 and free T4 plasma concentrations. Interestingly, a clearcut clinical amelioration was observed in both patients even before a reduction of circulating free thyroid hormone concentrations could be documented. In conclusion, our experience indicates that plasmapheresis may be useful in order to obtain a rapid amelioration of severe clinical picture of thyrotoxicosis, but cannot be considered as a definite therapy in AIIT. It should be considered that plasmapheresis is not devoid of risks and is also a very expensive procedure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8144857     DOI: 10.1007/BF03348934

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  13 in total

1.  The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone-induced thyrotoxicosis.

Authors:  B Uzzan; E Pussard; A Leon; D Bekhechi; A Krivitzky; E Modigliani; G Perret; R Vassy; A Berdeaux; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

2.  Potassium Perchlorate and Aplastic Anaemia.

Authors: 
Journal:  Br Med J       Date:  1961-05-27

3.  Hyperthyroidism as a possible complication of the treatment of ischemic heart disease with amiodarone.

Authors:  M H Jonckheer; P Blockx; R Kaivers; G Wyffels
Journal:  Acta Cardiol       Date:  1973       Impact factor: 1.718

4.  Fatal complications following use of potassium perchlorate in thyrotoxicosis. Report of two cases and a review of the literature.

Authors:  D Barzilai; M Sheinfeld
Journal:  Isr J Med Sci       Date:  1966 Jul-Aug

5.  Prednisone in amiodarone-induced thyrotoxicosis.

Authors:  C Wimpfheimer; M Stäubli; J Schädelin; H Studer
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-19

6.  Measurement of free thyroid hormones in serum by column adsorption chromatography and radioimmunoassay.

Authors:  P B Romelli; F Pennisi; L Vancheri
Journal:  J Endocrinol Invest       Date:  1979 Jan-Mar       Impact factor: 4.256

7.  Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole.

Authors:  E Martino; F Aghini-Lombardi; S Mariotti; M Lenziardi; L Baschieri; L E Braverman; A Pinchera
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

8.  Plasma exchange and hemoperfusion in iodine-induced thyrotoxicosis.

Authors:  L Preuschof; F Keller; U Bogner; E Reuter; G Offermann
Journal:  Blood Purif       Date:  1991       Impact factor: 2.614

9.  Iodine-induced thyrotoxicosis: analysis of eighty-five consecutive cases.

Authors:  A F Leger; J P Massin; M F Laurent; M Vincens; M Auriol; O B Helal; G Chomette; J C Savoie
Journal:  Eur J Clin Invest       Date:  1984-12       Impact factor: 4.686

10.  Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands.

Authors:  C Broussolle; X Ducottet; C Martin; Y Barbier; H Bornet; G Noel; J Orgiazzi
Journal:  J Endocrinol Invest       Date:  1989-01       Impact factor: 4.256

View more
  8 in total

1.  High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment.

Authors:  S Mariotti; A Loviselli; S Murenu; F Sau; L Valentino; A Mandas; S Vacquer; E Martino; A Balestrieri; M E Lai
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  Iopanoic acid rapidly controls type I amiodarone-induced thyrotoxicosis prior to thyroidectomy.

Authors:  F Bogazzi; F Aghini-Lombardi; C Cosci; I Lupi; F Santini; M L Tanda; P Miccoli; F Basolo; A Pinchera; L Bartalena; L E Braverman; E Martino
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

Review 3.  Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy.

Authors:  C M Newman; A Price; D W Davies; T A Gray; A P Weetman
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

4.  Preoperative Therapeutic Plasma Exchange and Surgical Treatment in Thyrotoxicosis Patients: A Single-Centre Retrospective Cohort Study.

Authors:  H Yabanoglu; R Sari; F Eksi Haydardedeoglu; M Kus; A S Hargura; I M Arer
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

5.  Total thyroidectomy for medically refractory amiodarone-induced thyrotoxicosis.

Authors:  Ankit N Mehta; Raphaelle D Vallera; Chad R Tate; Rebecca A Sager; Brian J Welch
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-10

6.  Managing thyroid dysfunction in selected special situations.

Authors:  Durr E Sabih; Mohammad Inayatullah
Journal:  Thyroid Res       Date:  2013-02-04

7.  Amiodarone-induced thyrotoxic thyroiditis: a diagnostic and therapeutic challenge.

Authors:  Umang Barvalia; Barkha Amlani; Ram Pathak
Journal:  Case Rep Med       Date:  2014-11-12

8.  Severe Hyperthyroidism Complicated by Agranulocytosis Treated with Therapeutic Plasma Exchange: Case Report and Review of the Literature.

Authors:  Vishnu Garla; Karthik Kovvuru; Shradha Ahuja; Venkatataman Palabindala; Bharat Malhotra; Sohail Abdul Salim
Journal:  Case Rep Endocrinol       Date:  2018-01-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.